Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 4 of 4 for “"TRAIL receptor"”.
-
Production and Characterization of an Human Monoclonal Antibody IgG to TRAIL Receptor 2
… Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) 은 TNF superfamily에 속하며, 수용성 TRAIL의 경우 DR4와 DR5및 결합하여 다양한 암세포에 세포독성을 가질 뿐 만 아니라, 정상세포에서는 세포독성이 적어 암 치료제로서 가능성이 높게 평가되고 있다. 그러나 수용성 TRAIL의 경우 불안정하며, 사람의 hepatocytes에서 세포독성을 일으킬 수 있고, TRAIL에 의한 저항성을 가지는 암세포 또한 보고된 바 있다. 따라서 현재는 TRAIL을 대체 할 수 있는 …
-
Towards ultrahigh-throughput phenotypic screening using microfluidic droplets and functionalised polyacrylamide beads
… on the potency of apoptosis induction for two TRAIL-receptor agonists, observing that potency is strongly dependent on agonist valency and therefore likely also on microdomain formation (‘lipid rafting’) for TRAIL-receptor. We use multimerisation to achieve a ~5 pM EC50 for a multivalent …
-
Characterization of Cytotoxicity against Cancer Cells induced by Human Monoclonal Antibody Specific to TRAIL-R1
… facter-related apoptosis-inducing ligand (TRAIL) is a member of the TNF ligand superfamily. Soluble TRAIL(sTRAIL) induces apoptosis in a variety of tumor cells through activation of TRAIL-R1 (DR4) and TRAIL- R2 (DR5) with no effect on most normal cells. Also, Tumor cells that are resistant …
-
Development of novel antibody-targeted nanoparticle strategies for treatment of pancreatic cancer
… the TNF-related apoptosisinducing ligand (TRAIL) receptor 2/ death receptor-5 (DR5) pathway using the monoclonal antibody conatumumab (AMG 655). However, the results of these clinical trials proved disappointing with no survival advantage being observed. Subsequent literature has suggested …